What's gut got to do with it? The role of the microbiota and inflammation in the development of adiposity and obesity-Immunometabolism-CSCIED科技核心评价数据库-手机版

What's gut got to do with it? The role of the microbiota and inflammation in the development of adiposity and obesity

What's gut got to do with it? The role of the microbiota and inflammation in the development of adiposity and obesity

ES评分 0 浏览量：596 下载量：0

全文阅读下载引用收藏

DOI	10.1097/IN9.0000000000000029
刊名	Immunometabolism IJ
年，卷(期)	2023, 5(3)
作者	Jennings, Travis; Janquart, Mallory; Washak, Catherine; Duddleston, Khrystyne; Kurtz, Courtney,
作者单位	[Jennings, Travis; Duddleston, Khrystyne] Univ Alaska Anchorage, Dept Biol Sci, Anchorage, AK USA; [Janquart, Mallory; Washak, Catherine; Kurtz, Courtney] Univ Wisconsin, Dept Biol, Oshkosh, WI 54901 USA
摘要	Obesity is a complex and heterogeneous disease characterized by increased adiposity, ie, the accumulation of lipids and the growth of adipose tissue. In this mini-review, we explore the important role of the gut microbiota and immune system in the development of adiposity. Dysbiosis of the microbiota leads to increased permeability of the gut barrier and bacterial products in the bloodstream, which triggers metabolic inflammation of adipose tissue, muscle, and liver. Inflammation in these highly metabolic organs exacerbates adiposity and contributes to the development of comorbidities associated with obesity. Studies in animal models that manipulate the microbiota and/or inflammation have shown promise in the treatment of obesity.
Abstract	Obesity is a complex and heterogeneous disease characterized by increased adiposity, ie, the accumulation of lipids and the growth of adipose tissue. In this mini-review, we explore the important role of the gut microbiota and immune system in the development of adiposity. Dysbiosis of the microbiota leads to increased permeability of the gut barrier and bacterial products in the bloodstream, which triggers metabolic inflammation of adipose tissue, muscle, and liver. Inflammation in these highly metabolic organs exacerbates adiposity and contributes to the development of comorbidities associated with obesity. Studies in animal models that manipulate the microbiota and/or inflammation have shown promise in the treatment of obesity.
关键词	gut microbiota; white adipose tissue; liver; skeletal muscle; cytokines
KeyWord	gut microbiota; white adipose tissue; liver; skeletal muscle; cytokines
基金项目
页码	1-6

参考文献
相关文献

[1]. Woods SC. The control of food intake: behavioral versus molecular perspectives. Cell Metab. 2009;9(6):489–98.

[2]. Suriano F, Vieira-Silva S, Falony G, et al. Fat and not sugar as the determining factor for gut microbiota changes, obesity, and related metabolic disorders in mice. Am J Physiol Endocrinol Metab. 2023;324(1):E85–96.

[3]. Agagunduz D, Icer MA, Yesildemir O, et al. The roles of dietary lipids and lipidomics in gut-brain axis in type 2 diabetes mellitus. J Transl Med. 2023;21(1):240.

[4]. Agus A, Clement K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174–82.

[5]. Allam-Ndoul B, Castonguay-Paradis S, Veilleux A. Gut microbiota and intestinal trans-epithelial permeability. Int J Mol Sci . 2020;21(17):6402.

[6]. Forgie AJ, Fouhse JM, Willing BP. Diet-microbe-host interactions that affect gut mucosal integrity and infection resistance. Front Immunol. 2019;10:1802.

[7]. Scheithauer TPM, Rampanelli E, Nieuwdorp M, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:571731.

[8]. Chelakkot C, Choi Y, Kim DK, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med. 2018;50(2):e450.

[9]. Moreira AP, Texeira TF, Ferreira AB, et al. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr. 2012;108(5):801–9.

[10]. Guo X, Li S, Zhang J, et al. Genome sequencing of 39 Akkermansia muciniphila isolates reveals its population structure, genomic and functional diverisity, and global distribution in mammalian gut microbiotas. BMC Genomics. 2017;18(1):800.

[11]. Zhai Q, Feng S, Arjan N, et al. A next generation probiotic, Akkermansia muciniphila. Crit Rev Food Sci Nutr. 2019;59(19):3227–36.

[12]. Parada Venegas D, De la Fuente MK, Landskron G, et al. Short Chain Fatty Acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.

[13]. Lee EY, Bang JY, Park GW, et al. Global proteomic profiling of native outer membrane vesicles derived from Escherichia coli. Proteomics. 2007;7(17):3143–53.

[14]. Horstman AL, Kuehn MJ. Bacterial surface association of heat-labile enterotoxin through lipopolysaccharide after secretion via the general secretory pathway. J Biol Chem. 2002;277(36):32538–45.

[15]. Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev. 2005;19(22):2645–55.

[16]. Le CE, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541–6.

[17]. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–4.

[18]. Pinart M, Dotsch A, Schlicht K, et al. Gut microbiome composition in obese and non-obese persons: a systematic review and meta-analysis. Nutrients. 2021;14(1):12.

[19]. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–5.

[20]. Pascale A, Marchesi N, Marelli C, et al. Microbiota and metabolic diseases. Endocrine. 2018;61(3):357–71.

[21]. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137(5):1716–24.e1.

[22]. Lam YY, Ha CW, Campbell CR, et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One. 2012;7(3):e34233.

[23]. Kang Y, Kang X, Yang H, et al. Lactobacillus acidophilus ameliorates obesity in mice through modulation of gut microbiota dysbiosis and intestinal permeability. Pharmacol Res. 2022;175:106020.

[24]. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103.

[25]. Moya-Perez A, Neef A, Sanz Y. Bifidobacterium pseudocatenulatum CECT 7765 reduces obesity-associated inflammation by restoring the lymphocyte-macrophage balance and gut microbiota structure in high-fat diet-fed mice. PLoS One. 2015;10(7):e0126976.

[26]. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3(3):207–15.

[27]. Hamilton MK, Boudry G, Lemay DG, et al. Changes in intestinal barrier function and gut microbiota in high-fat diet-fed rats are dynamic and region dependent. Am J Physiol Gastrointest Liver Physiol. 2015;308(10):G840–51.

[28]. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240–73, Table of Contents.

[29]. Taniguchi Y, Yoshioka N, Nakata K, et al. Mechanism for maintaining homeostasis in the immune system of the intestine. Anticancer Res. 2009;29(11):4855–60.

[30]. Liu W, Crott JW, Lyu L, et al. Diet- and genetically-induced obesity produces alterations in the microbiome, inflammation and Wnt pathway in the intestine of Apc(+/1638N) mice: comparisons and contrasts. J Cancer. 2016;7(13):1780–90.

[31]. Luck H, Tsai S, Chung J, et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 2015;21(4):527–42.

[32]. Rohm TV, Fuchs R, Muller RL, et al. Obesity in humans is characterized by gut inflammation as shown by pro-inflammatory intestinal macrophage accumulation. Front Immunol. 2021;12:668654.

[33]. Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129(10):3990–4000.

[34]. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380(1-2):24–30.

[35]. Blaszczak AM, Jalilvand A, Hsueh WA. Adipocytes, innate immunity and obesity: a mini-review. Front Immunol. 2021;12:650768.

[36]. Kunz HE, Hart CR, Gries KJ, et al. Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity. Am J Physiol Endocrinol Metab. 2021;321(1):E105–21.

[37]. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808.

[38]. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.

[39]. Hill DA, Lim HW, Kim YH, et al. Distinct macrophage populations direct inflammatory versus physiological changes in adipose tissue. Proc Natl Acad Sci U S A. 2018;115(22):E5096–105.

[40]. Lopez-Perez D, Redruello-Romero A, Garcia-Rubio J, et al. In patients with obesity, the number of adipose tissue mast cells is significantly lower in subjects with type 2 diabetes. Front Immunol. 2021;12:664576.

[41]. LaMarche NM, Kohlgruber AC, Brenner MB. Innate T cells govern adipose tissue biology. J Immunol. 2018;201(7):1827–34.

[42]. Caspar-Bauguil S, Cousin B, Andre M, et al. Weight-dependent changes of immune system in adipose tissue: importance of leptin. Exp Cell Res. 2006;312(12):2195–202.

[43]. Brinker G, Froeba J, Arndt L, et al. CD4(+) T cells regulate glucose homeostasis independent of adipose tissue dysfunction in mice. Eur J Immunol. 2021;51(6):1399–411.

[44]. Strissel KJ, DeFuria J, Shaul ME, et al. T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity (Silver Spring). 2010;18(10):1918–25.

[45]. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930–9.

[46]. Zeyda M, Huber J, Prager G, et al. Inflammation correlates with markers of T-cell subsets including regulatory T cells in adipose tissue from obese patients. Obesity (Silver Spring). 2011;19(4):743–8.

[47]. Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017;127(1):43–54.

[48]. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol. 2004;287(4):C834–43.

[49]. Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017;35:200–21.

[50]. Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, et al. Human adipocytes induce inflammation and atrophy in muscle cells during obesity. Diabetes. 2015;64(9):3121–34.

[51]. Zhu S, Tian Z, Torigoe D, et al. Aging- and obesity-related peri-muscular adipose tissue accelerates muscle atrophy. PLoS One. 2019;14(8):e0221366.

[52]. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, et al. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes. 2001;50(10):2337–43.

[53]. Krssak M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 1999;42(1):113–6.

[54]. Perseghin G, Scifo P, De Cobelli F, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 1999;48(8):1600–6.

[55]. Kim HJ, Higashimori T, Park SY, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004;53(4):1060–7.

[56]. Borst SE, Lee Y, Conover CF, et al. Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle but not adipose tissue. Am J Physiol Endocrinol Metab. 2004;287(5):E934–8.

[57]. Hong EG, Ko HJ, Cho YR, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. 2009;58(11):2525–35.

[58]. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32:S157–63.

[59]. Assuncao SNF, Sorte N, Alves CAD, et al. Inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD) in obese children and adolescents. Nutr Hosp. 2018;35(1):78–83.

[60]. Breuer DA, Pacheco MC, Washington MK, et al. CD8(+) T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020;318(2):G211–24.

[61]. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208.

[62]. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94(6):2557–62.

[63]. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343(20):1467–76.

[64]. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103(6):1372–9.

[65]. Salles J, Tardif N, Landrier JF, et al. TNFalpha gene knockout differentially affects lipid deposition in liver and skeletal muscle of high-fat-diet mice. J Nutr Biochem. 2012;23(12):1685–93.

[66]. Neyrinck AM, Van Hee VF, Piront N, et al. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes. 2012;2:e28.

[67]. Jiang T, Gao X, Wu C, et al. Apple-derived pectin modulates gut microbiota, improves gut barrier function, and attenuates metabolic endotoxemia in rats with diet-induced obesity. Nutrients. 2016;8(3):126.

[68]. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096–103.

[69]. Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107–13.

[70]. Kopp L, Schweinlin A, Tingo L, et al. Potential modulation of inflammation and physical function by combined probiotics, omega-3 supplementation and vitamin D supplementation in overweight/obese patients with chronic low-grade inflammation: a randomized, placebo-controlled trial. Int J Mol Sci . 2023;24(10):8567.

[71]. Guedes MR, Pontes K, Barreto Silva MI, et al. Randomized controlled trials reporting the effects of probiotics in individuals with overweight and obesity: a critical review of the interventions and body adiposity parameters. Clin Nutr. 2023;42(6):835–47.

[72]. Soltani S, Ashoori M, Dehghani F, et al. Effects of probiotic/synbiotic supplementation on body weight in patients with diabetes: a systematic review and meta-analyses of randomized-controlled trials. BMC Endocr Disord. 2023;23(1):86.

[73]. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108(3):437–46.

[74]. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293(5535):1673–7.

[75]. Nixon M, Wake DJ, Livingstone DE, et al. Salicylate downregulates 11beta-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012;61(4):790–6.

[76]. Nilsson C, Raun K, Yan FF, et al. Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin. 2012;33(2):173–81.

[77]. Gordon-Larsen P, French JE, Moustaid-Moussa N, et al. Synergizing mouse and human studies to understand the heterogeneity of obesity. Adv Nutr. 2021;12(5):2023–34.

[78]. Hatton JJ, Stevenson TJ, Buck CL, et al. Diet affects arctic ground squirrel gut microbial metatranscriptome independent of community structure. Environ Microbiol. 2017;19(4):1518–35.

[79]. Florant GL, Lawrence AK, Williams K, et al. Seasonal changes in pancreatic B-cell function in euthermic yellow-bellied marmots. Am J Physiol. 1985;249(2 Pt 2):R159–65.

[80]. Sonsalla MM, Love SL, Hoh LJ, et al. Development of metabolic inflammation during pre-hibernation fattening in 13-lined ground squirrels (Ictidomys tridecemlineatus). J Comp Physiol B. 2021;191(5):941–53.

[81]. Agagunduz D, Gencer Bingol F, Celik E, et al. Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions. J Transl Med. 2022;20(1):460.

[82]. Agagunduz D, Kocaadam-Bozkurt B, Bozkurt O, et al. Microbiota alteration and modulation in Alzheimer’s disease by gerobiotics: The gut-health axis for a good mind. Biomed Pharmacother. 2022;153:113430.

[83]. Ortega MA, Alvarez-Mon MA, Garcia-Montero C, et al. Microbiota-gut-brain axis mechanisms in the complex network of bipolar disorders: potential clinical implications and translational opportunities. Mol Psychiatry. 2023. doi: 10.1038/s41380-023-01964-w.

引用本文

Jennings, Travis; Janquart, Mallory; Washak, Catherine; Duddleston, Khrystyne; Kurtz, Courtney. What's gut got to do with it? The role of the microbiota and inflammation in the development of adiposity and obesity [J]. Immunometabolism. 2023; 5; (3). 1 - 6.

文献评论

相关学者

相关机构